Long-term, low-dose lithium treatment does not impair renal functional in the elderly: A 2 year randomized, placebo-controlled trial followed by single blind extension (2014)
- Authors:
- USP affiliated authors: GATTAZ, WAGNER FARID - FM ; FORLENZA, ORESTES VICENTE - FM
- Unidade: FM
- DOI: 10.4088/JCP.13m08741
- Subjects: LÍTIO (APLICAÇÕES TERAPÊUTICAS); EVENTO ADVERSO A MEDICAMENTO; TRANSTORNO BIPOLAR (TERAPIA); PLACEBO; ESTUDOS RANDOMIZADOS
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Journal Clinical of Psychiatrist
- Volume/Número/Paginação/Ano: v. 75, n. 7, p. e672-e678, 2014
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
APRAHAMIAN, Ivan et al. Long-term, low-dose lithium treatment does not impair renal functional in the elderly: A 2 year randomized, placebo-controlled trial followed by single blind extension. Journal Clinical of Psychiatrist, v. 75, n. 7, p. e672-e678, 2014Tradução . . Disponível em: https://doi.org/10.4088/JCP.13m08741. Acesso em: 19 set. 2024. -
APA
Aprahamian, I., Santos, F. S., Santos, B. dos, Talib, L., Diniz, B. S., Radanovic, M., et al. (2014). Long-term, low-dose lithium treatment does not impair renal functional in the elderly: A 2 year randomized, placebo-controlled trial followed by single blind extension. Journal Clinical of Psychiatrist, 75( 7), e672-e678. doi:10.4088/JCP.13m08741 -
NLM
Aprahamian I, Santos FS, Santos B dos, Talib L, Diniz BS, Radanovic M, Gattaz WF, Forlenza OV. Long-term, low-dose lithium treatment does not impair renal functional in the elderly: A 2 year randomized, placebo-controlled trial followed by single blind extension [Internet]. Journal Clinical of Psychiatrist. 2014 ; 75( 7): e672-e678.[citado 2024 set. 19 ] Available from: https://doi.org/10.4088/JCP.13m08741 -
Vancouver
Aprahamian I, Santos FS, Santos B dos, Talib L, Diniz BS, Radanovic M, Gattaz WF, Forlenza OV. Long-term, low-dose lithium treatment does not impair renal functional in the elderly: A 2 year randomized, placebo-controlled trial followed by single blind extension [Internet]. Journal Clinical of Psychiatrist. 2014 ; 75( 7): e672-e678.[citado 2024 set. 19 ] Available from: https://doi.org/10.4088/JCP.13m08741 - Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study
- Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression
- Inhibition of phospholipase A2 in rat brain decreases the levels of total Tau protein
- Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease
- Decreased Levels of Circulating Adiponectin in Mild Cognitive Impairment and Alzheimer’s Disease
- Lithium reduces Gsk3b mRNA levels: implications for Alzheimer Disease
- Mild cognitive impairment (part 2): biological markers for diagnosis and prediction of dementia in Alzheimer's disease
- Low Doses of Lithium Changes PKA, AKT and Tau Protein in Cortical and Hippocampal Neurons Cell Culture
- Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression
- Inhibition of phospolipase A2 modulates glycogen synthase activity and tau phosphorylation in primary cultures of cortical and hippocampal neurons
Informações sobre o DOI: 10.4088/JCP.13m08741 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
